Diagnostic criteria for neuromyelitisoptica spectrum disorders

Belova A.N.; Boĭko A.N.; Belova E.M.

doi:https://doi.org/10.17116/jnevro20161162232-40

Close metadata

Recommended articles:

Cognitive impairment in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73

Low-level laser therapy in multiple sclerosis: justification and optimization methods of application. (Literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(5):45-56

Glial fibrillary acidic protein: is there a relationship with the course of multiple sclerosis and traumatic brain injury before the onset of multiple sclerosis?. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):80-84

An individual approach to the diagnosis and treatment of an acute psychotic condition in a patient with a multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):97-102

Surgical treatment of secondary trigeminal neuralgia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):203-209

Quality of life of patients with multiple sclerosis in the Smolensk region. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):36-40

Hormonal contraception methods and multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):24-30

Epidemiology of multiple sclerosis in the city of Novosibirsk. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):119-127

Comparing the efficacy of divozilimab and second-line treatments for relapsing-remitting multiple sclerosis in the Russian Federation: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68

A clinical case of X-linked adrenoleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107

Abstract:

The review is devoted to revised international diagnostic criteria for neuromyelitisoptica spectrum disorders (NMOSD).Current diagnostic criteria allow NMOSD diagnosis not only for serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG)-seropositive patients but for AQP4-IgG-seronegative patients as well. New criteria are expected to make NMOSD diagnosis earlier and more accurate as well as to facilitate the differentiation with multiple sclerosis. Furthermore, unify international criteria should help to perform comparable epidemiologic studies and clinical trials of new drugs for NMOSD.

Keywords:

neuromyelitisoptica (NMO)

multiple sclerosis

neuromyelitisoptica spectrum disorders (NMOSD)

aquaporin-4 immunoglobulin G antibodies (AQP4-IgG)

diagnostic criteria

Authors:

Belova A.N.

Yaroslavl Regional Clinical Oncological Hospital, Yaroslavl, Russia

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Scopus AuthorID: 57224826008
ORCID: 0000-0001-6476-6417

Belova E.M.

Nizhny Novgorod State Medical Academy, Nizhniy Novgorod

Close metadata

References:

Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805-815.
Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation. 2013;10:8-12. doi: 10.1186/1742-2094-10-8.
Albutt TC. On the ophthalmoscopic signs of spinal disease. Lancet. 1870;1:76-78.
Devic E. Myelite subaiguë compliquee de neurite optique. Bull Med. 1894;8.
Gault F. De la neuromyelite optique aiguë. Lyon, thesis. 1894.
Beck GM. A case of diffuse myelitis associated with optic neuritis. Brain. 1927;50.
Matiello M, Weinshenker B. Neuromyelitis optica. In: Lucchinetti C.F., Hohlfeld R. Multiple sclerosis 3. Saunders Elsevier. 2010;258-275.
Wingerchuk DM, Weinshenker B. Unusual presentations and variants of idiopathic central nervous system demyelinating disease. In: Raine C., McFarland H., Hohlfeld R. (eds). Multiple sclerosis. Saunders Elsevier. 2008;32-38.
Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology. 1999;53:1107-1114.
Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O, Kümpfel T. Neuromyelitis Optica Study Group (NEMOS): Update on the diagnosis and treatment of of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261:1-16. doi: 10.1007/s00415-013-7169-7.
Lennon VA, Wingerchuk DM, Kryzer TJ et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106-2112.
Misu T, Takahashi T, Nishiyama S, Takano R, Nakashima I, Fujihara K, Itoyama Y. New insights into the pathogenesis of neuromyelitis optica. Brain Nerve. 2010;62(9):921-931.
Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485-1489.
Asgari N, Lillevang ST, Skejoe H, Falah M, Stenager E, Kyvik KO. A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011;76:1589-1595. doi: 10.1212/wnl.0b013e3182190f74.
Cabrera-Gomez JA, Kurtzke JF, Gonzalez-Quevedo A, Lara-Rodriguez R. An epidemiological study of neuromyelitis optica in Cuba. J Neurol. 2009;256:35-44.
Miller DH, Weinshenker BG, Filippi M et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler. 2008;14:1157-1174.
Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, Du Pasquier RA, Polman CH, Sorensen PS, Hemmer B. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17(8):1019-1032.
Kimbrough D, Fujihara K, Jacob A et al. Treatment of Neuromyelitis Optica: Review and Recommendations. Mult Scler Relat Disord. 2012;1:180-187.
Jarius S, Paul F, Franciotta D et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci. 2011;306:82-90. doi: 10.1016/j.jns.2011.03.038.
Lu Z, Zhang B, Qiu W, Kang Z, Shen L, Long Y, Huang J, Hu X. Comparative brain stem lesions on MRI of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. PLoS One. 2011;6:22766.
Apiwattanakul M, Popescu BF, Matiello M et al. Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol. 2010;68:757-761. doi: 10.1002/ana.22121.
Popescu BFG, Lennon VA, Parisi JE et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology. 2011;76:1229-1237. doi: 10.1212/wnl.0b013e318214332c.
Waters PJ, McKeon A, Leite MI et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012;78:665-671. doi: 10.1212/wnl.0b013e318248dec1.
Sato DK, Nakashima I, Takahashi T et al. Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology. 2013;80:2210-2216. doi: 10.1212/wnl.0b013e318296ea08.
Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, Weinshenker BG. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008;70:2197-2200.
Jarius S, Frederikson J, Waters P et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci. 2010;298:158-162. doi: 10.1016/j.jns.2010.07.011.
Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, Plant GT. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatr. 2010;81:109-111. doi: 10.1136/jnnp.2008.146894.
Simaniv T.O., Vtorova N.V., Vorob'eva A.A., Zigangirova N.A., Zakharova M.N. Diagnosticheskoe znachenie antitel k akvaporinu-4 pri zabolevaniyakh tsentral'noi nervnoi sistemy. Neirokhimiya. 2014;3:246-253.
Simaniv T.O., Vorob'eva A.A., Smirnova N.V., Zigangirova N.A., Zakharova M.N. Optikomielit i akvaporin-assotsiirovannye sindromy. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2015;115: 2:2:31-37.
Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock S, Lucchinetti CF, Lennon VA. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006;59:566-569.
Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler. 2012;18:1480-1483.
Palace J, Leite MI, Nairne A, Vincent A. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol. 2010;67:1016-1017. doi: 10.1001/archneurol.2010.188.
Shimizu J, Hatanaka Y, Hasegawa M, Iwata A, Sugimoto I et al. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology. 2010;75:1423-1427. doi: 10.1212/wnl.0b013e3181f8832e.
Barnett M, Prineas J, Buckland M, Parratt J, Pollard J. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler. 2012;18:108-112. doi: 10.1177/1352458511421185.
Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012;69:239-245. doi: 10.1001/archneurol.2011.216.
Kitley J, Evangelou N, Küker W, Jacob A, Leite MI, Palace J. Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab. J Neurol Sci. 2014;339:223-225. doi: 10.1016/j.jns.2014.01.035.
Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012;18:113-115. doi: 10.1177/1352458511431973.
Izaki S et al. A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions following fingolimod treatment. Rin.sho Shinkeigaku. 2013;53:513-517.
Wingerchuk DM, Banwell V, Bennett J et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189. doi: 10.1212/wnl.0000000000001729.
Sato DK, Callegaro D, Lana-Peixoto MA et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82:474-481. doi: 10.1212/wnl.0000000000000101.
Kim JE, Kim SM, Ahn SW et al. Brain abnormalities in neuromyelitis optica. J Neurol Sci. 2011;302:43-48. doi: 10.1016/j.jns.2010.12.001.
Kim W, Kim SH, Lee SH, Li XF, Kim HJ. Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder. Mult Scler. 2011;17:1107-1112. doi: 10.1177/1352458511404917.
Magana SM, Matiello M, Pittock SJ et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology. 2009;72:712-717. doi: 10.1212/01.wnl.0000343001.36493.ae.
Bourre B, Zephir H, Ongagna JC et al. Long-term follow-up of acute partial transverse myelitis. Arch Neurol. 2012;69:357-362. doi: 10.1001/archneurol.2011.949.
Kremer L, Mealy M, Jacob A et al. Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler. 2014;20:843-847.
Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin-4 expression. Arch Neurol. 2006;63:964-968.
Kim SM, Go MJ, Sung JJ, Park KS, Lee KW. Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics. Arch Neurol. 2012;69:1026-1031. doi: 10.1001/archneurol.2012.112.
Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005;65:1479-1482.
Jarius S, Ruprecht K, Wildemann B et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:14. doi: 10.1186/1742-2094-9-14.
Kanbayashi T, Shimohata T, Nakashima I, Yaguchi H, Yabe I, Nishizawa M, Shimizu T, Nishino S. Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. Arch Neurol. 2009;66:1563-1566. doi: 10.1001/archneurol.2009.264.
Suzuki K, Nakamura T, Hashimoto K, Miyamoto M, Komagamine T et al. Hypothermia, hypotension, hypersomnia, and obesity associated with hypothalamic lesions in a patient positive for the anti-aquaporin-4 antibody: a case report and literature review. Arch Neurol. 2012;69:1355-1359.
Schmidt F, Önder G, Jarius S, Wildemann B, Ruprecht K, Paul F, Harms L. Olfactory dysfunction in patients with neuromyelitis optica. Mult Scler Int. 2013;2013:654501. doi: 10.1155/2013/654501.
Flanagan EP, Weinshenker BG, Krecke KN et al. Short myelitis lesions in aquaporin-4-IgG—positive neuromyelitis optica spectrum disorders. JAMANeurol. 2015;72:81-87. doi: 10.1001/jamaneurol.2014.2137.
Kim W, Park MS, Lee SH et al. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. MultScler. 2010;16:1229-1236. doi: 10.1177/1352458510376640.
Huh SY, Min JH, Kim W et al. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. Mult Scler. 2014;20:695-704. doi: 10.1177/1352458513506953.
Matthews L, Marasco R, Jenkinson M et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology. 2013;80:1330-1337. doi: 10.1212/wnl.0b013e3182887957.
Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006;63:390-396.
Nakamura M, Misu T, Fujihara K et al. Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Mult Scler. 2009;15:695-700. doi: 10.1177/1352458509103301.
Waters P, Pittock SJ, Bennett JL, Jarius S, Weinshenker BG. Wingerchuk DM. Evaluation of aquaporin-4 antibody assays. Clin ExpNeuroimmunol. 2014;5;290-303.
Pittock SJ, Lennon VA, Bakshi N et al. Seroprevalence of aquaporin-4—IgG in a northern California population representative cohort of multiple sclerosis. JAMA Neurol. 2014;71:1433-1436. doi: 10.1001/jamaneurol.2014.1581.
Jarius S, Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol. 2013;23:661-683. doi: 10.1111/bpa.12084.
Marignier R, Bernard-Valnet R, Giraudon P et al. Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology. 2013;80:2194-2200. doi: 10.1212/wnl.0b013e318296e917.
Kitley J, Waters P, Woodhall M et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. 2014;71:276-283. doi: 10.1001/jamaneurol.2013.5857.
Kitley J, Woodhall M, Waters P et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012;79:1273-1277. doi: 10.1212/wnl.0b013e31826aac4e.
Jarius S, Aboul-Enein F, Waters P et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008;131:3072-3080. doi: 10.1093/brain/awn240.
Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler. 2012;18:5-10. doi: 10.1177/1352458511431077.
Kuroiwa Y, Shibasaki H. Epidemiologic and clinical studies of multiple sclerosis in Japan. Neurology. 1976;26:8-10.
Banwell B, Tenembaum S, Lennon VA et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology. 2008;70:344-352.
McKeon A, Lennon VA, Lotze T et al. CNS aquaporin-4 autoimmunity in children. Neurology. 2008;71:93-100.
Krupp LB, Tardieu M, Amato MP et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. 2013;19:1261-1267. doi: 10.1177/1352458513484547.